A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
22/06/2022at 11:49

"We have suffered a significant financial loss as a consequence of Vifor's conduct," says Pharmacosmos

The Swiss firm has demonstrated anticompetitive behavior for 12 years on markets where it competes with Pharmacosmos, claims the Danish firm after having officially complained to the EU Commission.
Pharmacosmos's chief operating officer, Tobias S. Christensen (right), and chief executive officer, Lars Christensen (left) | Photo: Pharmacosmos / PR
by mikkel aabenhus hemmingsen & christopher due karlsson, translated by daniel pedersen

For years on end, Vifor Pharma has been shutting out Pharmacosmos from the intravenous (IV) iron deficiency drug market, says the Danish family-owned business, claiming it has consequently lost out on considerable income.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Vifor Pharma / PR

    Vifor Pharma denies having spread false information about Pharmacosmos

    For subscribers

  • Søren Tulstrup previously served as CEO of Vifor Pharma, and is currently the CEO of Hansa Biopharma | Photo: Hansa Biopharma

    Former Vifor Pharma CEO had no knowledge of alleged Pharmacosmos smear campaign

    For subscribers

  • Margrethe Vestager, EU Commissioner for Competition | Photo: Jennifer Jacquemart / European Union/European Commission

    EU opens antitrust investigation into Vifor Pharma for trashing rival Pharmacosmos

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Photo: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Photo: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Foto: Yves Herman
Medtech

EU Commission to give more time for MDR transition

A proposal meant to mitigate potential medical device shortages under the Medical Device Regulation is now headed to the European Parliament and Council under an accelerated procedure.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Foto: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Head of International Sales

  • Commercial Director

  • Application Manager

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

See all jobs

Jobs

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Head of International Sales

  • Commercial Director

  • Application Manager

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge